Commissioning and dose verification of contemporary brachytherapy treatment planning systems
Advanced dose calculation algorithms have been introduced recently in commercially available TPSs in an effort to reduce Type B uncertainties associated with inhomogeneities and finite patient dimensions, and improve accuracy of 192Ir HDR brachytherapy. These algorithms calculate dose in computational models defined from patient imaging and are therefore collectively referred to as model-based dose calculation algorithms (MBDCAs).
Due to the complexity of MBDCA algorithmic implementation, the association of their results to an image-based computational model and the use of basic input data that are not accessible by the clinical end users, dosimetry testing for acceptance, commissioning, and quality assurance purposes can no longer rely on verification of data entry and simple spreadsheet calculations, as for TG-43-based TPSs.
After a short introduction to clinically available MBDCAs, this presentation will focus on the commissioning approach based on DICOM-RT test cases set forth by an international working group, and discuss the potential of experimental dose verification in the clinical setting.